NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF

• US 20090258947A1
• Filed: 04/23/2007
• Published: 10/15/2009
• Est. Priority Date: 04/24/2006
• Status: Abandoned Application

• Current Assignee: Panacea Biotec Limited
• Original Assignee: Panacea Biotec Limited
• Inventors: Jain, Rajesh, Jindal, Kour Chand
• Application Number:
  US12/298,054
• Publication Number:
  US 20090258947A1
• Time in Patent Office: Days
• US Class Current: 514/608
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/485 Inorganic compounds
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

Claims

1. A novel low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof, with one or more pharmaceutically acceptable excipient(s).

2. The novel low dose pharmaceutical dosage form according to claim 1, wherein the total daily dose of nimesulide is less than the conventionally administered daily dose of at least about 200 mg of nimesulide.

3. The novel low dose pharmaceutical dosage form according to claim 2, wherein the dose of the nimesulide is in an amount below 200 mg, intended for once-a-day administration.

4. The novel low dose pharmaceutical dosage form according to claim 3, wherein the dose of the nimesulide is in an amount ranges form about 125 mg to about 180 mg, intended for once-a-day administration.

5. The novel low dose pharmaceutical dosage form according to claim 3, wherein the low dose of the nimesulide intended for once-a-day administration is administered either in single unit or in a multiple unit.

6. The novel low dose pharmaceutical dosage form according to claim 5, wherein the low dose of the nimesulide intended for once-a-day administration is administered in a single unit, preferably in the form of tablet.

7. The novel low dose pharmaceutical dosage form according to claim 2, wherein the individual dose of the nimesulide is in an amount below 100 mg, for a single administration intended for twice-a-day administration.

8. The novel low dose pharmaceutical dosage form according to claim 7, wherein the individual dose of the nimesulide is in an amount ranges from about 25 mg to about 85 mg, for a single administration intended for twice-a-day administration.

9. The novel low dose pharmaceutical dosage form according to claim 1, wherein the pharmaceutically acceptable excipient(s) is selected amongst polymeric material, gum, surfactant, complexing agent, diluents, disintegrants, binders, mucoadhesive agents, fillers, bulking agents, anti-adherants, anti-oxidants, buffering agents, colorants, flavoring agents, coating agents, plasticizers, stabilizers, preservatives, lubricants, glidants, chelating agents, used either alone or in combination.

10. The novel low dose pharmaceutical dosage form according to claim 1, wherein the dosage form additionally comprises one or more other active agent(s) selected amongst antipyretics, antiallergics, aldosterone receptor antagonists, antibiotics, various enzymes, antimuscarinic agents, anti-viral agents, protein kinase inhibitors, β

2-adrenergic agonist, ACE inhibitors, opoid analgesics, steroids, leukotriene B4(LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, HMG CoA inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, bronchodilators, spasmolytics, muscle relaxants, proton pump inhibitors, isoprostane inhibitors, PDE4-inhibitors, other NSAIDs, selective or preferential COX-2 inhibitors, COX-1 inhibitors, expectorants, analgesics, antiemetics, urinary acidifiers, antidepressants, antipsychotics, antimigraine agents, and the like or mixtures.

11. The novel low dose pharmaceutical dosage form according to claim 1, wherein the dosage form is selected amongst tablets, capsules, liquid dispersions, oral suspensions, gels, aerosols, ointments, creams, fast melt formulations, lyophilized formulations, injectables, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and a combination of immediate release and controlled release formulations.

12. The novel low dose pharmaceutical dosage form according to claim 11, wherein the dosage form is in the form of tablet, which may be coated with one or more functional or non-functional coating layers.

13. The novel low dose pharmaceutical dosage form according to claim 1, wherein the dosage form is prepared by a process comprises of the following steps:

i) treating nimesulide with one or more pharmaceutically acceptable excipient(s),

ii) optionally adding one or more other active agent(s), and

iii) formulating into a suitable dosage form.

14. The novel low dose pharmaceutical dosage form according to claim 1, wherein the dosage form is capable of providing therapeutically effective bioavailability of nimesulide with reduced side effects, after dosing in a human subject.

15. The novel low dose pharmaceutical dosage form according to claim 1, wherein the dosage form is useful in the management of cyclooxygenase enzyme mediated disorders and/or cyclooxygenase inhibitor indicated disorders.

16. The method of using a novel low dose pharmaceutical dosage form according to claim 1, for the treatment of NSAID indicated disorders, early morning pathologies, post-operative trauma, pain associated with cancer, postoperative pain, sports injuries, dysmenorrhoea, migraine headache, neurological pain and pain associated with sciatica and spondylitis, arthritis, idiopathic pain, myofascial pain, osteoarthitis, neuropathic pain, fibromyalgia and inflammatory pain states;

cancer pain;

chronic pain;

sympathetically mediated pain, Raynaud'"'"'s disease, CPS (Chronic Pain Syndrome);

tension and migraine headache, stump pain, polyarteritis nodosa, osteomyelitis, burns involving nerve damage, AIDS related pain syndromes, and connective tissue disorders, other degenerative joint disorders, or any other disorders mediated by particularly the cyclooxygenase enzyme, pain and/or inflammation associated with osteoarthritis, ligamentous pain, bursitis, tendinitis, low back pain, postoperative pain, dental extraction or surgery;

saphenectomy or inguinal hemioplasty;

haemorrhoidectomy;

acute musculoskeletal injury;

ear, nose or throat disorders;

gynaecological disorders;

cancer pain;

alzheimer'"'"'s disease;

thrombophlebitis;

urogenital disorders;

bursitis or tendonitis;

morning stiffness associated with rheumatoid arthritis, shingles, trigeminal neuralgia, temporomandibular joint disorder;

cancer pain or a combination of several disorders or any other associated disorder.

17. (canceled)